From drug discovery to predictive analytics, here’s how emerging tech companies are disrupting the CRO model.
Return on investment for drug R&D has declined by over 80% in the past decade.
To combat this downward trend, pharmaceutical companies now outsource about 50% of R&D to contract research organizations (CROs), which can help bring down costs.
CROs leverage emerging technologies — such as AI for drug discovery, digital twins for clinical trials, and real-world evidence — to help clients develop drugs. Increasingly, they also support data integration, predictive analytics, and patient engagement efforts at healthcare enterprises.
Want the full expert post? Become a CB Insights customer.
If you’re already a customer, log in here.
